|
|
CPDI-02 |
|
Vaxjo ID |
154 |
|
Vaccine Adjuvant Name |
CPDI-02 |
|
Adjuvant VO ID |
VO_0006093
|
|
Description |
A vaccine adjuvant that is a peptide which is able to induce Th1/Th2/Th17 immune responses through the mechanism of selectively activates C5aR1 on mononuclear phagocytes vs neutrophils. |
|
Stage of Development |
Research |
|
Location Licensed |
US (University of Nebraska Medical Center) |
|
Host Species for Testing |
3 |
|
Second Host Species for Testing |
4 |
|
Components |
residue substitutions designed to restrict backbone flexibility in C5a65-74. devoid of c5a like neutrophil and neutropenic activities |
|
Storage |
4C w/ desiccation |
|
Preparation |
were synthesized by solid-phase methods (https://pmc.ncbi.nlm.nih.gov/articles/PMC2997863/#R19) |
|
Function |
induced the release of the pro-inflammatory cytokines IL-6, TNFα, and INFγ from splenic APCs |
| References |
(Vetro, 2023): Vaccine Adjuvant Compendium (VAC) [https://vac.niaid.nih.gov/view?id=40]
Vogen et al., 2001: Vogen SM, Paczkowski NJ, Kirnarsky L, Short A, Whitmore JB, Sherman SA, Taylor SM, Sanderson SD. Differential activities of decapeptide agonists of human C5a: the conformational effects of backbone N-methylation. International immunopharmacology. 2001; 1(12); 2151-2162. [PubMed: 11710544].
|
|
